These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

970 related articles for article (PubMed ID: 29741648)

  • 21. Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis.
    Hofstetter L; Naegelin Y; Filli L; Kuster P; Traud S; Smieskova R; Mueller-Lenke N; Kappos L; Gass A; Sprenger T; Penner IK; Nichols TE; Vrenken H; Barkhof F; Polman C; Radue EW; Borgwardt SJ; Bendfeldt K
    Mult Scler; 2014 Feb; 20(2):202-13. PubMed ID: 23804554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study.
    Bakshi R; Benedict RH; Bermel RA; Caruthers SD; Puli SR; Tjoa CW; Fabiano AJ; Jacobs L
    Arch Neurol; 2002 Jan; 59(1):62-8. PubMed ID: 11790232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of lesional and extra-lesional cortical grey matter in relapsing-remitting and secondary progressive multiple sclerosis: A magnetisation transfer and diffusion tensor imaging study.
    Yaldizli Ö; Pardini M; Sethi V; Muhlert N; Liu Z; Tozer DJ; Samson RS; Wheeler-Kingshott CA; Yousry TA; Miller DH; Chard DT
    Mult Scler; 2016 Feb; 22(2):150-9. PubMed ID: 26014608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis.
    Fisniku LK; Altmann DR; Cercignani M; Tozer DJ; Chard DT; Jackson JS; Miszkiel KA; Schmierer K; Thompson AJ; Miller DH
    Mult Scler; 2009 Jun; 15(6):668-77. PubMed ID: 19435751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study.
    Tedeschi G; Dinacci D; Comerci M; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Patti F; Morra VB; Servillo G; Orefice G; Paciello M; Prinster A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Brunetti A; Salemi G; D'Amelio M; Simone I; Salvatore M; Bonavita V; Alfano B
    Mult Scler; 2009 Feb; 15(2):204-11. PubMed ID: 18987104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis.
    Abdel-Aziz K; Schneider T; Solanky BS; Yiannakas MC; Altmann DR; Wheeler-Kingshott CA; Peters AL; Day BL; Thompson AJ; Ciccarelli O
    Brain; 2015 Jun; 138(Pt 6):1568-82. PubMed ID: 25863355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability.
    Roosendaal SD; Bendfeldt K; Vrenken H; Polman CH; Borgwardt S; Radue EW; Kappos L; Pelletier D; Hauser SL; Matthews PM; Barkhof F; Geurts JJ
    Mult Scler; 2011 Sep; 17(9):1098-106. PubMed ID: 21586487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
    Fisniku LK; Brex PA; Altmann DR; Miszkiel KA; Benton CE; Lanyon R; Thompson AJ; Miller DH
    Brain; 2008 Mar; 131(Pt 3):808-17. PubMed ID: 18234696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study.
    Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Barkhof F; Schoonheim MM; Strijbis EM; Vrenken H; Gallo A; Bisecco A; Ciccarelli O; Yiannakas M; Rovira A; Sastre-Garriga J; Palace J; Matthews L; Gass A; Eisele P; Lukas C; Bellenberg B; Margoni M; Preziosa P; Filippi M;
    J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):10-18. PubMed ID: 36171105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Staging of cortical and deep grey matter functional connectivity changes in multiple sclerosis.
    Meijer KA; Eijlers AJC; Geurts JJG; Schoonheim MM
    J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):205-210. PubMed ID: 28986469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Impact of Intracortical Lesions on Volumes of Subcortical Structures in Multiple Sclerosis.
    Kalinin I; Makshakov G; Evdoshenko E
    AJNR Am J Neuroradiol; 2020 May; 41(5):804-808. PubMed ID: 32381540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deep grey matter MRI abnormalities and cognitive function in relapsing-remitting multiple sclerosis.
    Debernard L; Melzer TR; Alla S; Eagle J; Van Stockum S; Graham C; Osborne JR; Dalrymple-Alford JC; Miller DH; Mason DF
    Psychiatry Res; 2015 Dec; 234(3):352-61. PubMed ID: 26602610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.
    Paling D; Solanky BS; Riemer F; Tozer DJ; Wheeler-Kingshott CA; Kapoor R; Golay X; Miller DH
    Brain; 2013 Jul; 136(Pt 7):2305-17. PubMed ID: 23801742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal changes of deep gray matter shape in multiple sclerosis.
    Tsagkas C; Geiter E; Gaetano L; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Kappos L; Sprenger T; Granziera C; Mallar Chakravarty M; Magon S
    Neuroimage Clin; 2022; 35():103137. PubMed ID: 36002960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis.
    Meijboom R; York EN; Kampaite A; Harris MA; White N; Valdés Hernández MDC; Thrippleton MJ; MacDougall NJJ; Connick P; Hunt DPJ; Chandran S; Waldman AD;
    PLoS One; 2023; 18(7):e0288967. PubMed ID: 37506096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.
    Crescenzo F; Marastoni D; Zuco C; Pitteri M; Magliozzi R; Monaco S; Calabrese M
    Mult Scler Relat Disord; 2019 Jan; 27():305-311. PubMed ID: 30453199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study.
    Bonacchi R; Meani A; Pagani E; Marchesi O; Filippi M; Rocca MA
    J Neurol; 2022 Jul; 269(7):3841-3857. PubMed ID: 35230471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
    Zivadinov R; Sepcic J; Nasuelli D; De Masi R; Bragadin LM; Tommasi MA; Zambito-Marsala S; Moretti R; Bratina A; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of deep grey matter volume on cognition in multiple sclerosis.
    Lorefice L; Carta E; Frau J; Contu F; Casaglia E; Coghe G; Barracciu MA; Cocco E; Fenu G
    Mult Scler Relat Disord; 2020 Oct; 45():102351. PubMed ID: 32731200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A voxel-based morphometry study of disease severity correlates in relapsing-- remitting multiple sclerosis.
    Prinster A; Quarantelli M; Lanzillo R; Orefice G; Vacca G; Carotenuto B; Alfano B; Brunetti A; Morra VB; Salvatore M
    Mult Scler; 2010 Jan; 16(1):45-54. PubMed ID: 20028706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.